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Abstract Tetrakis-, tris-, bis-, and mono salicylic acid
derivatives 1–4 were synthesized by reaction of methyl
2-hydroxy benzoate (methyl salicylate) with 2,2-bis
(hydroxymethyl) propane-1,3-diol (pentaerythritol) in the
presence of sodium. Yields of different salicyloyloxy
derivatives were changed by varying the molar ratios of
reactants. For compounds 2 and 3, X-ray structure analysis
was performed, as well as molecular energy minimization,
to define their conformation in terms of their energy min-
ima. Comparison of crystal and energy minimized struc-
tures for these two compounds (2 and 3) revealed that the
intramolecular hydrogen bonds play an important role,
stabilizing conformation of the most part of the molecule.
The antioxidant activity and cytotoxicity of the synthesized
derivatives were evaluated in a series of in vitro tests, as
well as 17b-hydroxysteroid dehydrogenase type 2 inhibi-
tion potency. Tetrakis salicyloyloxy derivative 1 expressed
the highest antioxidant potency, tris salicyloyloxy deriva-
tive 2 was the best inhibitor of 17bHSD2 enzyme, while bis
salicyloyloxy derivative 3 showed strong cytotoxicity
against prostate and breast cancer cells with no cytotoxicity
against healthy cells.
Keywords Salicylic acid derivatives  Antioxidant
activity  Cytotoxicity  Antitumor activity  17b-
hydroxysteroid dehydrogenase type 2 (17bHSD2)
inhibitors  Energy minimization  X-ray structural analysis
Introduction
Attacking biomolecules and thus causing cell or tissue
injury, free radicals, originating from metabolism or
external sources, could be included in the development of
many life-limiting chronic diseases: cancer, cardiovascular
diseases, rheumatism, and others [1, 2]. Increasing of
antioxidants level in the body could be an effective way to
prevent or exceed oxidative stress, where compounds with
antioxidant potency may play a significant role. Creation or
isolation from natural sources of new molecules with
antioxidant properties is a very actual research area, since
many naturally occurring or synthetic phenol substances
proved to be strong antioxidants. Many phenol substances
expressed anticancer activity against various types of car-
cinomas [3–8].
Salicylic acid derivatives, being phenol substances, are
biologically very potent: some of them exhibited cytotox-
icity against tumor cell lines, some showed antioxidant
properties. In many cases, these two activities are con-
nected [9–16].
In addition, some phenol substances could influence on
the level of circulating steroids by affecting the steroido-
genic enzymes, which is of high significance for the
treatment of different endocrine disorders [17, 18]. For
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example, some phenol substances expressed themselves as
good inhibitors of 17b-hydroxysteroid dehydrogenase type
2 (17bHSD2), so they are used for the treatment of oste-
oporosis [19].
Having in mind all of these facts, in the present study,
we continue our investigation of the synthesis of salicylic
acid derivatives, which was described in previous papers
[14, 15, 20, 21]. We report a simple synthetic route for the
preparation of mono-, bis-, tris-, and tetrakis salicyloyl
derivatives of 2,2-bis(hydroxymethyl)-propane-1,3-diol
(pentaerythritol). Two new compounds were obtained as
monocrystals, which allowed their structural analysis.
Biochemical studies included testing of antioxidant activ-
ity, cytotoxicity, and 17bHSD2 inhibition potency.
Experimental
Chemical synthesis
General
IR spectra were recorded on a NEXUS 670 SP-IR spec-
trometer (wave numbers in cm-1). NMR spectra were
taken on a Bruker AC 250E spectrometer operating at
250 MHz (1H) and 62.5 MHz (13C) and are reported in
ppm (d-scale) downfield from the tetramethylsilane inter-
nal standard; coupling constants (J) are given in Hz. Mass
spectra were recorded on a Finnigan MAT 8230 instru-
ment, using chemical ionization (isobutane) technique. All
the reagents used were of analytical grade. All solutions
were dried over anhydrous Na2SO4.
General procedure for the synthesis of propane-1,3-diyl
2,2-bis(2-hydroxybenzoyloxy)methyl bis(2-hydroxybenzoate)
(1), propane-1,3-diyl 2-((2-hydroxybenzoyloxy)methyl)-
2-(hydroxymethyl) bis(2-hydroxybenzoate) (2), propane-1,3-
diyl 2,2-bis(hydroxymethyl) bis(2-hydroxybenzoate) (3) and
3-hydroxy-2,2-bis(hydroxymethyl)propyl 2-hydroxybenzoate
(4).
A mixture consisting of methyl 2-hydroxybenzoate
(methyl salicylate; 148 mmol or 23 mmol), 2,2-bis
(hydroxymethyl)propane-1,3-diol (pentaerythritol, 37 or
92 mmol), and sodium (3.7 or 7 mmol) was heated on an
oil bath at 150 C under atmospheric pressure with the
continuos removal of methanol for 2 h. Afterward, distilled
water (50 mL) and hydrochloric acid (1:1, to pH 6–7) were
added to the residue. The crude product was extracted with
ethyl acetate or dichloromethane (5 9 50 mL), dried (anh.
Na2SO4), and evaporated. Pure compounds were obtained
after chromatography of crude product on silica gel column
(25 g).
When molar ratio of methyl salicylate (148 mmol) and
2,2-bis(hydroxymethyl)propane-1,3-diol (37 mmol) was
4:1, the precipitated solid of crude product, obtained after
reaction completion, was chromatographed on silica gel
column (benzene; benzene–ethyl acetate, 9:1) to give pure
compound 1 in a yield of 1 % (0.126 g) after recrystalli-
zation from dichloromethane–hexane, mp 174–175 C.
Pure compound 2 was obtained in a yield of 19 %
(2.141 g) after recrystallization from ethyl acetate–hexane,
mp 138–139 C. With further elution with benzene–ethyl
acetate (4:1) pure compound 3 was obtained in a yield of
13 % (2.00 g) after recrystallization from acetone–hexane,
mp 86.5–87 C ( [21] 86.5–87 C).
According to the general procedure, when molar ratio
of methyl 2-hydroxybenzoate (23 mmol) and 2,2-bis
(hydroxymethyl)propane-1,3-diol (92 mmol) was 1:4 (in the
presence of sodium, 7 mmol), the pure compounds 2–4 were
obtained after column chromatography (benzene–ethyl ace-
tate, 9:1, 2:1 and 1:3). Compound 2 was obtained in a yield
of 3 % (0.337 g, mp 138 C from dichloromethane–hex-
ane), compound 3 in a yield of 18 % (0.809 g, mp 87 C
from dichloromethane–hexane), and compound 4 in a yield
of 3 % (0.470 g, mp 174–175 C from dichloromethane–
hexane [22]. In this reaction procedure, compound 1 was not
isolated.
Compound 1: IR (KBr): 3214, 1681, 1614, 1583, 1298,
1247, 1211, 1158, 1157, 1090, 755. 1H NMR (CDCl3):
4.73 (s, 8H, 4CH2); 6.86 (m, 4H, 4H-5 from A,B,C,D
rings); 6.98 (dd, 4H, 4H-3 from A,B,C,D rings,
J(3,4) = 8.3 Hz, J(3,5) = 1.0 Hz); 7.49 (m, 4H, 4H-4 from
A,B,C,D rings); 7.80 (dd, 4H, 4H-6 from A,B,C,D rings,
J(6,4) = 1.6 Hz, J(6,5) = 8.0 Hz); 10.47 (s, 4H, 4OH from
A,B,C,D rings). 13C NMR (CDCl3): 43.14 (C(CH2)4);
63.31 (4CH2); 111.45 (4C-1 from A,B,C,D rings); 117.88
(4C-3 from A,B,C,D rings); 119.44 (4C-5 from A,B,C,D
rings); 129.48 (4C-6 from A,B,C,D rings); 136.39 (4C-4
from A,B,C,D rings); 161.83 (4C-2 from A,B,C,D rings);
169.39 (4C=O). MS (m/z, rel %): 617 (M??1, 100); 616
(M?, 7); 478 (15). For C33H28O12 9 0.3C6H6 (639.6)
calculated: 65.31 % C, 4.66 % H; found: 65.33 % C,
5.01 % H.
Compound 2: IR (KBr): 3550–3200, 2961, 1678, 1614,
1585, 1485, 1466, 1396, 1325, 1299, 1248, 1212, 1157,
1089, 756, 699. 1H NMR (CDCl3): 2.54 (bs, 1H, CH2OH);
3.85 (s, 2H, CH2OH); 4.63 (s, 6H, 3CH2OCO); 6.87 (m,
3H, 3H-5 from A,B,C rings); 6.99 (dd, 3H, 3H-3 from
A,B,C rings, J(3,4) = 8.2 Hz, J(3,5) = 1.1 Hz); 7.48 (m, 3H,
4H-4 from A,B,C rings); 7.79 (dd, 3H, 3H-6 from A,B,C
rings, J(6,4) = 1.5 Hz, J(6,5) = 8.1 Hz); 10.53 (s, 3H, 3OH
from A,B,C rings). 13C NMR (CDCl3): 44.86 (C(CH2)4);
60.79 (CH2OH); 63.19 (3CH2OCO); 111.64 (3C-1 from
A,B,C rings); 117.84 (3C-3 from A,B,C rings); 119.40 (3C-
5 from A,B,C rings); 129.60 (3C-6 from A,B,C rings);
136.30 (3C-4 from A,B,C rings); 161.77 (3C-2 from A,B,C
rings); 169.79 (3C=O). MS (m/z, rel %): 497 (M??1, 55);
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496 (M?, 100); 376 (12). For C26H24O10 9 0.8H2O
(510.8) calculated: 61.13 % C, 5.01 % H; found: 60.94 %
C, 4.53 % H.
Compound 3 was synthesized in our previous paper
[21].
Compound 4: IR (KBr): 3550–3100, 1680, 1620, 1600,
1300, 1250, 1210, 1070, 980, 760. 1H NMR (CDCl3): 3.73
(d, 6H, 3CH2OH, J = 4.9 Hz); 4.08 (m, 3H, 3CH2OH);
4.44 (s, 2H, CH2OCO); 6.94 (m, 2H, H-5 and H-3 from A
ring); 7.52 (m, 1H, H-4 from A ring); 7.89 (dd, 1H, H-6
from A ring J(6,4) = 1.8 Hz, J(6,5) = 8.2 Hz); 10.74 (s, 1H,
OH from A ring). 13C NMR (CDCl3): 46.00 ((CH2)
C(CH2OH)3); 62.72 (3CH2OH); 65.23 (CH2OCO); 113.57
(C-1 from A ring); 118.17 (C-3 from A ring); 120.07 (C-5
from A ring); 130.86 (C-6 from A ring); 136.53 (C-4 from
A ring); 162.20 (C-2 from A ring); 170.73 (C=O). MS (m/z,
rel %): 257 (M??1, 100); 239 (2); 161 (2); 120 (2). For
C12H16O6 (256.2) calculated: 56.24 % C, 6.29 % H; found:
56.36 % C, 6.05 % H.
Crystal structure determination
The diffraction data for compounds 2 and 3 were collected
at room temperature on an Oxford Diffraction (Agilent
Technologies) Xcalibur diffractometer with graphite-
monochromated MoKa radiation (k = 0.7107 A˚). The data
reduction was performed with program package CrysAlis
RED [23]. The space group determinations were based on
an analysis of the Laue class and the systematically absent
reflections. The structures were solved by direct methods
using SIR92 [24]. All structures were refined using full-
matrix least-squares. For all three compounds, non-hydro-
gen atoms were refined anisotropically, the C–H hydrogen
atoms were included on calculated positions riding on their
attached atoms with fixed distances 0.97 A˚ (CH2) and
0.96 A˚ (CH3). At the final stage of the refinement, H atoms
from the hydroxyl group were positioned geometrically
(O–H = 0.82 A˚) and refined using a riding model with
fixed isotropic displacement parameters. All calculations
were performed using SHELXL97 [25], PARST [26], and
PLATON [27], as implemented in the WINGX [28] system
of programs. The crystal data and refinement parameters
are summarized in Table 1.
Biological tests
Free radical scavenging assays
Free radical scavenging capacity (RSC) of the synthesized
compounds was evaluated by measuring their ability to
neutralize 2,2-diphenyl-1-picrylhydrazyl (DPPH) and HO
radicals. Final concentrations of the tested compounds
were in the range of 0.01–8 mM.
DPPH assay
The DPPH assay was performed as described before [14].
The different aliquots (0.10–2.00 mL) of 0.01 M sample
solution in methanol were added to 1.00 mL of 90 lM
DPPH in methanol (Sigma; St. Louis, MO) and filled up
with 95 % (v/v) methanol to a final volume of 4.00 mL.
The same reaction mixture without the tested compounds
was used as the control. Absorbencies of the reaction
mixtures and control were recorded at 515 nm (CECIL
CE2021 spectrophotometer) after 1 h. Commercial syn-
thetic antioxidants, 3,5-di-tert-butyl-4-hydroxytoluene
(BHT) (Aldrich; Taufkirchen, Germany) and 3-tert-butyl-
4-hydroxyanisole (BHA) (Fluka; Taufkirchen, Germany)
were used as positive controls. For each sample, three
replicates were recorded.
The percentage of DPPH radical scavenging capacity
(DPPH RSC) was calculated using the following equation:
RSC %ð Þ ¼ 100  Acontrol  Asample=Acontrol
 
:
IC50 values (the concentration of the tested compound in
the reaction mixture which causes 50 % of RSC) were
determined by linear regression analysis from the obtained
RSC values.
Hydroxyl-radical scavenging assay
Hydroxyl-radicals scavenging capacity (OH RSC) of the
tested compounds was evaluated by measuring the degra-
dation of 2-deoxy-D-ribose (Aldrich; Taufkirchen, Ger-
many) in the reaction with OH radicals, generated in situ
in Fenton’s reaction [14]. These radicals attack 2-deoxy-D-
ribose and degrade it into a series of fragments, some or all
of which react with 2-thiobarbituric acid (TBA) (Sigma; St.
Louis, MO) at low pH and high temperature to give a pink
chromogen, which can be determined spectrophotometri-
cally at 532 nm. Different aliquots (0.005–0.5 mL) of
sample solution in methanol were added to test tubes (final
concentration ranged from 0.01 to 8 mM), each containing
0.1 mL of 5 mM H2O2, 0.1 mL of 10 mM FeSO4, and
0.1 mL of 0.05 M 2-deoxy-D-ribose and 0.067 M KH2
PO4–K2HPO4 buffer pH 7.4 to a final volume of 3.00 mL.
The same reaction mixture without sample was used as the
control. After an incubation period of 1 h at 37 C, 2 mL
of TBA reagent (10.4 mL of 60 % (v/v) HClO4, 3 g TBA
and 120 g of trichloroacetic acid (Sigma; St. Louis, MO),
and 0.2 mL of 0.1 M EDTA (Sigma; St. Louis, MO) were
added to the reaction mixture, and the tubes were heated at
100 C for 20 min. After cooling, absorbencies of the
reaction mixtures and of the control were recorded at
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532 nm. Percentage of HO RSC was calculated using the
following equation:
RSC %ð Þ ¼ 100  Acontrol  Asample=Acontrol
 
Three replicates were recorded for each sample. BHT and
BHA were used as reference compounds. IC50 values (the
concentration at which 50 % of HO is neutralized) were
determined by linear regression analysis from the obtained
RSC values.
Cytotoxic activity
The cytotoxicity of the synthesized compounds was eval-
uated using previously described method [29]. The
chemotherapy drug doxorubicin (Dox), used as control,
was tested under the same experimental conditions.
Cell lines
Three human tumor and one normal cell lines were used in
this study: estrogen-receptor positive human breast ade-
nocarcinoma (ER?, MCF-7), estrogen-receptor negative
human breast adenocarcinoma (ER-, MDA-MB-231),
human prostate cancer (PC-3), and normal fetal lung
fibroblasts (MRC-5). These cells were grown in Dulbecco’s
modified Eagle’s medium with 4.5 % of glucose. Media
were supplemented with 10 % of fetal calf serum and
antibiotics (100 IU/mL of penicillin and 100 lg/mL of
Table 1 Experimental details: crystallographic data and refinement parameters
2 3
Chemical formula C26H24O10 C38H40O16
Mr 496.45 752.70
Cell setting, space group Hexagonal, R¯3 Monoclinic, P21/c
Temperature (K) 293 293
a (A˚), b (A˚), c (A˚) 8.5196 (3), 15.2951 (5),
28.0026 (9)
a (A˚), c (A˚) 13.3220 (7), 22.1447 (14)
b () 97.082 (3)
V (A˚3) 3,403.6 (3) 3,621.1 (2)
Z 6 4
Dx (mg m
-3) 1.447 1.381
Radiation type Mo Ka Mo Ka
l (mm-1) 0.11 0.11
Crystal size (mm) 0.54 9 0.53 9 0.24 0.48 9 0.27 9 0.16
Diffractometer Goniometer Xcalibur, detector: Sapphire3 (Gemini)
Absorption correction Multi-scan
CrysAlis PRO, Oxford Diffraction Ltd., Version 1.171.33.66 (release 28-04-2010
CrysAlis171.NET) (compiled Apr 28 2010,14:27:37) Empirical absorption correction using
spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm
Tmin 0.993 0.975
Tmax 1.000 1.000
No. of measured, independent and observed
reflections
2,388, 1,331, 944 18,533, 6,357, 3,585
Rint 0.013 0.036
(sin h/k)max (A˚
-1) 0.594 0.595
R[F2 [ 2r(F2)], wR(F2), S 0.048, 0.139, 1.08 0.044, 0.110, 0.90
No. of reflections 1,331 6,357
No. of parameters 123 494
No. of restraints 1 0
H-atom treatment H atoms treated by a mixture of independent and constrained
refinement
H-atom parameters
constrained
Weighting scheme w = 1/[r2(Fo
2) ? (0.0753P)2 ? 0.8349P]
where P = (Fo
2 ? 2Fc
2)/3
w = 1/[r2(Fo
2) ? (0.0582P)2]
where P = (Fo
2 ? 2Fc
2)/3
Dqmax, Dqmin (e A˚
-3) 0.40, -0.42 0.35, -0.27
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streptomycin; ICN Galenika). All cell lines were cultured
in flasks (Costar, 25 cm2) at 37 C in 100 % humidity
atmosphere and 5 % of CO2 incubator. Only viable cells
were used in the assay. Viability was determined by dye
exclusion assay with trypan blue.
Cytotoxicity assay
Cytotoxicity was evaluated by colorimetric sulforhodamine
B (SRB) assay [29]. In brief, single cell suspension
(5 9 103 cells) was plated into 96-well microtiter plates
(Costar, flat bottom). Plates were pre-incubated at 37 C in
a 5 % CO2 incubator during 24 h. Tested substances (at
final concentrations ranging from 10-8 to 10-4 M) were
added to all wells except the control ones. After incubation
period (48 h/37 C/5 % CO2), cytotoxicity assay was car-
ried out as follows: 50 lL of 80 % trichloroacetic acid was
added to all wells; an hour later, the plates were washed
with distilled water, and 75 lL of 0.4 % SRB was added to
all wells; 30 min later the plates were washed with citric
acid (1 %) and dried at room temperature. Finally, 200 lL
of 10 mM Tris (pH 10.5) basis was added to all wells.
Absorbance was measured on the microplate reader. The
wells containing complete medium only, without cells,
acted as blank. Cytotoxicity was calculated according to
the formula:
CI %ð Þ ¼ 1Asample=Acontrol
  100:
Two independent experiments were set out in quadru-
plicate for each concentration of the compound. The IC50
(value that defines the dose of compound that inhibits cell
growth by 50 %) of compounds was determined by Median
effect analysis.
Determination of 17bHSD2 activity and its inhibition
in the rat liver microsomal preparation
Inhibitory effects exerted on the 17bHSD2 activity by the
newly synthesized compounds (1–3) were investigated via
conversion of testosterone to androst-4-ene-3,17-dione
in vitro. Our previously published radioincubation method
for 3bHSD [30, 31] was modified and adapted to the
17bHSD2 measurements. Female rat liver expresses
17bHSD2 constitutively [32], and served as feasible source
of this isozyme. Liver tissue of adult female Wistar rats
was homogenized with an Ultra-Turrax in 0.1 M HEPES
buffer (pH 7.3) containing 1 mM EDTA and 1 mM dithi-
othreitol and microsomes were obtained with fractionated
centrifugation. Aliquots of the microsomal preparate were
incubated with 1 lM [14C]testosterone in the presence of
1 mM NAD. [14C]testosterone was added to the incubate in
10 lL of a 25 v/v% propylene glycol in HEPES buffer
solution, whereas test compounds were applied in 10 lL of
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Fig. 1 The structures of compounds (1–4) obtained in the reaction of
methyl salicylate with pentaerythritol
Table 2 Molar ratios of reactants and yields of compounds 1–4
Molar ratio
Compound Yield (%)
4:1 1:4
1 1 –
2 19 3
3 13 18
4 – 3
Fig. 2 ORTEP drawing of molecular structures of compound 2 with
the labeling of non-H atoms. Displacement ellipsoids are shown at the
30 % probability level and H atoms are drawn as spheres of arbitrary
radii. Intramolecular hydrogen bonds are shown as dashed lines
Struct Chem (2014) 25:1747–1758 1751
123
dimethyl sulfoxide solution. These organic solvent contents
of 200 lL final volume of the incubation medium did not
reduce the enzyme activity substantially. Incubation was
carried out at 37 C for 20 min and the enzymatic reaction
was stopped by the addition of ethyl acetate and freezing.
After extraction, unlabeled carriers of testosterone and the
product androst-4-ene-3,17-dione were added to the sam-
ples. The two steroids were separated by TLC on Kiesel-
gel-G (Merck Si 254 F) layers (0.25-mm thick) with the
solvent system diisopropyl ether-CH2Cl2 (50:50 v/v) and
UV spots were used to trace the separated steroids. Spots
were cut out and the radioactivity of the androst-4-ene-
3,17-dione formed and of the testosterone remaining was
measured by means of liquid scintillation counting. Test
compounds were applied at 50 lM concentrations and
control incubates without test substances were also pre-
pared in every series. At least two experiments were per-
formed with each test compound and the standard
deviations of the mean enzyme activity results were within
±10 %. IC50 values were determined for more potent
inhibitors. In this case, conversion was measured at five or
six different concentrations of the test compound between
0.1 and 50 lM. IC50 results were calculated by linear
regression analysis following a logit-log transformation of
the data, and the standard deviations were determined from
the fitted lines.
Results and discussion
Chemistry
Tetrakis-, tris-, bis-, and mono- salicyloyloxy derivatives
1–4 were synthesized by reaction of methyl salicylate with
2,2-bis (hydroxymethyl)propane-1,3-diol in the presence of
sodium, at 150 C for 2 h (Fig. 1). The molar ratios of
reactants were varied in order to increase the yield of the
desired products (Table 2). When molar ratio of methyl
salicylate and 2,2-bis (hydroxymethyl)propane-1,3-diol
was 4:1, tetrakis derivative 1 was obtained in only 1 %
yield, while it was not obtained when molar ratio of
reactants was 1:4. Tris derivative 2 was formed in the yield
of 19 % (molar ratio 4:1), while in ratio 1:4 only 3 % of 2
were obtained. Compound 3 was obtained in 18 and 13 %
yield, in molar ratios 1:4 and 4:1, respectively. Mono sal-
icylic acid derivative 4, however, was obtained only when
molar ratio was 1:4, in a very low yield (3 %).
Crystal structures analyses
An ORTEP drawings of molecular structures of compound
2 and 3 are depicted in Figs. 2 and 3, respectively, while
selected bond distances, bond angles, and torsion angles
within these compounds are given in Table 3.
Fig. 3 ORTEP drawing of molecular structures of compound 3 with the labeling of non-H atoms. Displacement ellipsoids are shown at the 30 %
probability level and H atoms are drawn as spheres of arbitrary radii. Intramolecular hydrogen bonds are shown as dashed lines
1752 Struct Chem (2014) 25:1747–1758
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Table 3 Selected bond lengths (A˚), angles () and torsion angles ()
Compound 2 Compound 3
Bond Bond
O1a–C1a 1.445 (3) O1a–C1a 1.454 (3)
O1b–C1b O1b–C1b 1.445 (2)
O1c–C1c O1c–C1c 1.443 (3)
O1d–C1d 1.442 (2)
O1a–C2a 1.340 (3) O1a––C2a 1.339 (2)
O1b–C2b O1b–C2b 1.340 (3)
O1c–C2c O1c–C2c 1.330 (2)
O1d–C2d 1.332 (3)
O2a–C2a 1.219 (2) O2a–C2a 1.216 (2)
O2b–C2b O2b–C2b 1.220 (2)
O2c–C2c O2c–C2c 1.215 (2)
O2d–C2d 1.210 (2)
C9–O4 1.3960 (10) O4a–C9a 1.425 (2)
C9–O4
0i O4b–C9b 1.420 (3)
C9–O4
00ii O4c–C9c 1.425 (2)
O4d–C9d 1.419 (3)
Angle Angle
C1bi–C1–C1cii 113.00 (13) C1a–C1–C1b 112.39 (17)
C1bi–C1–C1a C1d–C10–C1c 111.79 (18)
C1cii–C1–C1a
C1a–C1–C9 105.66 (15) C1a–C1–C9a 104.02 (15)
C1bi–C1–C9 C1b–C1–C9b 106.75 (16)
C1cii–C1–C9 C1c–C10–C9c 106.08 (16)
C1d–C10–C9d 106.09 (17)
O4–C9–C1 115.8 (3) O4a–C9a–C1 112.99 (16)
O40i–C9–C1 O4b–C9b–C1 111.27 (17)
O4
00ii–C9–C1 O4c–C9c–C10 113.69 (18)
O4d–C9d–C10 108.97 (18)
Torsion angle Torsion angle
C1a–C1–C9–O4 -65.2 (4) C1a–C1–C9b–O4b 58.5 (3)
C1bi–C1–C9–O40i C1b–C1–C9a–O4a 57.5 (2)
C1cii–C1–C9–O4
00ii C1c–C10–C9d–O4d -55.3 (2)
C1d–C10–C9c–O4c -53.6 (2)
C1a–C1–C9–O40i 54.8 (4) C9a–C1–C9b–O4b -57.2 (3)
C1bi–C1–C9–O4
00ii C9b–C1–C9a–O4a -61.0 (2)
C1cii–C1–C9–O4 C9c–C10–C9d–O4d 62.7 (2)
C9d–C10–C9c–O4c 64.3 (2)
C1a–C1–C9–O4ii 174.8 (4) C1a–C1–C9a–O4a 178.52 (16)
C1bi–C1–C9–O4 C1b–C1–C9b–O4b -178.1 (2)
C1cii–C1–C9–O4i C1c–C10–C9c–O4c -174.97 (17)
C1d–C10–C9d–O4d -176.76 (18)
C9–C1–C1A–O1a 166.69 (15) C9a–C1–C1a–O1a 175.12 (17)
C9b–C1–C1b–O1b 179.19 (17)
C2a–O1a––C1a–C1 178.92 (16) C9c–C10–C1c–O1c -170.63 (17)
C9d–C10–C1d––O1d -178.26 (18)
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Compound 2 crystallizes in hexagonal centrosymmetric
R-3 space group with threefold axis lying along the
direction of C1–C9 bond which means that the atoms C1
and C9 lie in the special position. The asymmetric unit
contains the fragment which has one-third of O4–H4
hydroxyl group and one-third of C1 and C9 (including the
hydrogen atoms attached to C9) atoms so the other two-
thirds are symmetry related. The location of O4 and H4
atoms in the unit cell is partial occupied with site occu-
pancy factor equal to 0.33 (Fig. 2 shows only one O4–H4
hydroxyl group and one pair of hydrogen atoms attached to
C9 for clarity). The molecular backbone of asymmetric
unit fragment is almost completely planar, except for a
rotation on the C1–C9 bond axis that bends the hydroxyl
group (see torsions on the C1–C9 bond in Table 3).
Compound 3 crystallizes in monoclinic centrosymmetric
P21/c space group with two molecules in the asymmetric
unit. Intramolecular geometry analysis showed that bond
lengths, angles, and torsion angles in molecule of com-
pound 2 are in agreement with the same region of com-
pound 3 (Table 3).
Hydrogen bonding analyses
The information on intramolecular hydrogen bonding, in
particular, is very useful to understand various molecular
properties (the molecular geometries, the stability of a
certain predominant conformation, and, consequently,
biological activity). As can be seen from Figs. 2 and 3,
both compounds (2 and 3) contain intramolecular O–H…O
hydrogen bonds connecting phenolic hydroxyl group and
salicyloyl carbonyl group. In molecular structure of com-
pound 3 two molecules in asymmetric unit are connected
by bifurcated, and therefore weaker, hydrogen bonds,
involving phenolic hydroxyl group and salicyloyl carbonyl
group. Bifurcation of donors and acceptors forms a circle
of hydrogen bonds. Crystal packings of two compounds (2
and 3) are illustrated in Fig. 4. As can be seen from Fig. 4a,
crystal packing of compound 3 is dominantly arranged by
the dense network of hydrogen bond mostly involving
O4(a,b,c,d) atom as donor or acceptor. The hydrogen bond
parameters are given in Table 4.
Since we wanted to investigate the antioxidant behavior
and cytotoxicity of compounds 2 and 3, we were interested
in the conformation of molecules released from the influ-
ence of crystalline field. The next step, after determining
the three-dimensional structures of these compounds in
crystalline state, was to define the conformation of the
molecules 2 and 3 in terms of energy minima. To do that
both molecular geometries were optimized (MMFF94 force
field: 500 steps of conjugate gradients followed by 500
steps of steepest descent with a convergence setting of
10e-7) using the program AVOGADRO 1.0.3 [34].
The conformation of molecules remains stable in their
energy minima in spite of the significant number of inter-
atomic single bonds. This is confirmed by comparing
selected torsion angles of molecules, obtained in crystal
structure analyses and after energy optimization (Table 5).
Figure 5 illustrates very good overlapping of the
molecular structures in crystalline state and after optimi-
zation for both compounds (2 and 3). It seems that the
presence of intramolecular hydrogen bonds in molecules
stabilizes their conformations in spite of the possible
influence of crystal packing. As illustrated in Fig. 5, the
intramolecular O–H…O hydrogen bonds in both com-
pounds (2 and 3) are preserved after energy minimization.
This is the conformation in which intramolecular hydrogen
bonds in compounds stabilize molecular conformation.
Biological properties
Antioxidant activity of the synthesized salicylic acid
derivatives
The in vitro antioxidant activity of the synthesized sali-
cyloyloxy derivatives was evaluated and compared with
those of commercial antioxidants BHT and BHA
(Table 6.). In the DPPH assay, the ability of tested com-
pounds to act as donors of hydrogen atoms or electrons in
transforming DPPH into its reduced form, DPPH-H, was
measured by spectrophotometric method [14]. All tested
Table 3 continued
Torsion angle Torsion angle
C1a–O1a–C2a–C3a 177.74 (18) C4a–C3a–C2a–O1a 169.49 (19)
C4b–C3b–C2b–O1b 177.04 (19)
C4a–C3a–C2a–O1a 175.95 (18) C4c–C3c–C2c–O1c -161.06 (19)
C4d–C3d–C2d–O1d 178.6 (2)
Symmetry code(s): (i) –y ? 1, x – y - 1, z; (ii) –x ?y ? 2, -x ? 1, z
Symmetry code: (i) –y ? 1, x – y - 1, z; (ii) –x ? y ? 2, -x ? 1, z
Symmetry code: (i) –y ? 1, x – y - 1, z; (ii) –x ? y ? 2, -x ? 1, z
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Fig. 4 Mercury [33] drawing showing the crystal packing of compound 2 (a) and 3 (b); hydrogen bonds are shown as dashed line
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compounds were able to reduce the stable purple-colored
radical DPPH into yellow-colored DPPH-H form, though
less than reference compounds (BHA and BHT). Among
three tested substances, compound 1, containing four sali-
cyloyl groups (IC50 0.35 mM), was the most potent, then
compound 2, containing three salicyloyl groups, and the
less potent was compound 3 possessing only two active
groups.
The hydroxyl-radical scavenging activity of the
examined compounds was measured by the deoxyribose
assay [14]. The protective effects of the tested compounds
on 2-deoxy-D-ribose were assessed as their ability to
remove hydroxyl radicals (formed in the Fenton reaction)
from the test solution and prevent the sugar degradation.
The OH radical scavenging activity of the tested com-
pounds was determined indirectly, by measuring the
absorbance of the pink-colored solutions. All three com-
pounds tested (1–3) expressed better scavenger properties
than reference compounds, while compound 1, possessing
four salicyloyl groups, was the most effective (IC50
0.40 mM).
Cytotoxicity of the synthesized salicylic acid derivatives
The cytotoxic effect of the synthesized compounds against
ER?human breast adenocarcinoma (MCF-7), ER-human
breast adenocarcinoma (MDA-MB-231), human prostate
cancer (PC-3), and normal fetal lung fibroblasts (MRC-5)
was examined by the standard SRB assay, after treatment
of cells with the tested compounds during 48 h [29]. The
results are presented in Table 6.
As can be seen in Table 6, bis salicyloyl derivative 3
expressed cytotoxicity against all three tumor cell lines,
while it was not toxic against healthy cells. Compound 3
showed the strongest cytotoxicity against prostate cancer
PC-3 cells, even 13 times stronger than doxorubicin, while
its effect was strong, but a little bit weaker against both
breast cancer cell lines, MCF-7 and MDA-MB-231.
Compounds 1 and 2 did not influence significantly on the
tumor cells proliferation.
It is very important to emphasize that none of the newly
synthesized compounds exhibited cytotoxicity against
healthy MRC-5 cells. On the contrary, doxorubicin was
highly toxic in very small doses.
Effects of the synthesized salicylic acid derivatives on rat
17bHSD2
Inhibitory effects exerted on the 17bHSD2 activity by the
newly synthesized compounds (1–3), investigated via
measurement of testosterone to androst-4-ene-3,17-dione
conversion by an adapted in vitro radiosubstrate incubation
method [30–32], emphasized tris salicyloyl derivative 2 as
the most potent 17bHSD2 inhibitor among the tested
compounds (Table 6). Namely, IC50 value for this
Table 4 Intramolecular O - H…O hydrogen bond parameters (A˚, )
D–H…A D–H H…A D…A D–H…A
Compound 2
O3a–H3a…O2a 0.82 1.93 2.645 (3) 146
O4–H4…O3a1 0.82 2.36 2.569 (7) 97
O40–H4…O3b1
O4
00
–H4…O3c1
Compound 3
O3a–H3a…O2a 0.82 1.94 2.632 (2) 142
O3a–H3a…O2c 0.82 2.58 3.047 (3) 118
O3b–H3b…O2b 0.82 1.94 2.657 (2) 145
O3b–H3b…O4a2 0.82 2.44 2.887 (2) 115
O3c–H3c…O2a 0.82 2.41 2.948 (3) 124
O3c–H3c…O2c 0.82 1.98 2.688 (2) 144
O3d–H3d…O2d 0.82 1.88 2.597 (2) 146
O4a–H4a…O3d3 0.82 1.96 2.764 (2) 167
O4b–H4b…O4c4 0.82 2.24 3.255 (3) 146
O4c–H4c…O4a5 0.82 2.00 2.753 (2) 152
O4d–H4d…O4c6 0.82 1.98 2.787 (2) 166
Symmetry codes: (1) x – y ? 1/3, ?x - 1/3-1, -z ? 2/3; (2) 1 -
x, -y, 1 - z; (3) 1 - x, -1/2?y,  - z; (4) 1 ? x, 1/2 - y,
1/2 ? z; (5) -1 ? x, 1/2 - y, -1/2 ? z; (6) -x, -y, -z
Table 5 Selected torsion angles ()
Crystal structure Energy minimization
Compound 2
C9–C1–C1A–O1a -65.2 (4) -63.5
C2a–O1a–C1a–C1 178.92 (16) 172.8
C1a–O1a–C2a–C3a 177.74 (18) 178.4
C1–O1a–C2a–O2a -2.9 (3) -2.4
Compound 3
C1a–C1–C9a–O4a 178.52 (16) -173.9
C1b–C1–C9a–O4a 57.5 (2) 66.1
C9b–C1–C9a–O4a -61.0 (2) -52.9
C1d–C10–C9d–O4d -176.76 (18) -177.7
C1c–C10–C9d–O4d -55.3 (2) -57
C9c–C10–C9d–O4d 62.7 (2) 61.8
C1a–O1a–C2a–O2a -6.0 (3) -2.4
C1a–O1a–C2a–C3a 174.27 (17) 179.3
C1b–O1b–C2b–O2b -0.6 (3) 1.1
C1b–O1b–C2b–C3b 179.50 (17) -179.5
C1c–O1c–C2c–O2c 2.9 (3) 2.1
C1c–O1c–C2c–C3c -178.48 (17) -179.3
C1d–O1d–C2d–O2d -2.1 (3) -0.9
C1d–O1d–C2d–C3d 178.17 (19) 179.4
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compound was 1.3 lM, which was 23 times stronger effect
than bis salicyloyl derivative 3 and much stronger than
tetrakis salicyloyl derivative 1.
Conclusion
The screening of biological properties of the newly syn-
thesized compounds 1–3 showed that they are pharma-
cologically promising substances, each in different areas
of antitumor drug search. Compound 1, containing four
salicyloyl groups, was the most potent radical scavenger.
Intramolecular geometry analysis of compound 2 and 3
(tris and bis salicyloyl derivatives) did not reveal major
differences in their conformations, so it seems that the
higher number of salicyloyl groups is the main reason for
better antioxidant activity. Tris salicyloyl derivative 2
was potent 17bHSD2 inhibitor. Bis salicyloyloxy deriv-
ative 3 showed strong cytotoxicity against prostate and
breast cancer cells, while it was not toxic against healthy
cells.
Comparison of crystal and energy optimized structures
for newly synthesized compounds 2 and 3 revealed that the
intramolecular hydrogen bonds play an important role,
stabilizing conformation of the most part of molecule. The
influence of crystal packing on molecular conformation,
including the dense network of intermolecular hydrogen
bond especially in compound 3, is not predominant.
Supplementary data
Supplementary data CCDC 994056 and 994057 contain the
supplementary crystallographic data for this paper. These
data can be obtained free of charge at www.ccdc.cam.ac.
uk/conts/retrieving.html [or from the Cambridge Crystal-
lographic Data Centre (CCDC), 12 Union Road, Cam-
bridge CB21EZ, UK; fax: ?44(0)1223-336033; email:
deposit@ccdc.cam.ac.uk].
Fig. 5 Superimposed fit of the molecules after energy minimization
(C atoms in green) and the molecule in the crystalline state (C atoms
in blue): a compound 2 and b compound 3 (Color figure online)
Table 6 Radical scavenger activities, in vitro cytotoxicity and in vitro inhibition of rat 17b-hydroxysteroid dehydrogenase type 2 (17bHSD2)
of salicyloyl derivatives (1–3) and reference compounds; At least two experiments were performed with each test compound for each activity
screening test, and the standard deviations of the mean results were within ±10 %
Comp. Radical scavenger activity IC50 (mM) Cytotoxicity IC50 (lM) 17bHSD2 inhibition
DPPH OH MCF-7 MDA-MB-231 PC-3 MRC-5 Rel. conv.a (%) IC50 (lM)
1 0.35 0.40 [100 [100 [100 [100 64 –
2 0.90 1.00 [100 [100 [100 [100 – 1.3
3 3.70 1.00 10.64 18.64 7.21 [100 39 30
BHT 0.04 1.94 – – – – – –
BHA 0.01 2.13 – – – – – –
DOX – – 0.75 0.12 95.61 0.12 – –
a Conversion measured in the presence of 50 lM of test compound, compared to conversion of control incubation with no inhibition (taken as 100 %)
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